The abstract is read at the publisher; the summary is JClub's.
In a single-arm pilot of high-risk Ki-67–high metastatic well-differentiated neuroendocrine tumors, pembrolizumab plus 177Lu-DOTATATE PRRT yielded a 35% RECIST v.1.1 ORR.
- Why it matters: Pre-treated Ki-67–high WD-NET can show limited durability with PRRT alone, and single-agent immune checkpoint inhibition has low response rates, motivating combination strategies.
- What they did: Twenty-six adults with WHO grade 2–3, somatostatin receptor–avid metastatic NET (Ki-67 index >10%) received concurrent pembrolizumab with 177Lu-DOTATATE PRRT; ORR was the primary endpoint by RECIST v.1.1.
- The result: Median PFS was 13.3 months (range 2.1–33.4) and median overall survival was 24.1 months (range 4.4–52.3), with severe adverse events in 14 (54%) patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.